---
title: "Brief-COPE Questionnaire Shows Five-Factor Structure in Seropositive Rheumatoid Arthritis"
id: "medrxiv-1-validation-of-the-brief-cope-questionnaire-in-a-seropositive-rheumatoid"
canonical_url: "https://medichelpline.com/clinical-feed/medrxiv-1-validation-of-the-brief-cope-questionnaire-in-a-seropositive-rheumatoid"
content_type: "clinical_feed_article"
specialty: "General"
source_name: "medRxiv (Clinical Preprints)"
source_url: "https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1?rss=1"
published_at: "2026-09-02T12:00:00.000Z"
evidence_level: "Verified Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Brief-COPE Questionnaire Shows Five-Factor Structure in Seropositive Rheumatoid Arthritis
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/medrxiv-1-validation-of-the-brief-cope-questionnaire-in-a-seropositive-rheumatoid
- **Specialty:** [General](https://medichelpline.com/clinical-feed/general.md)
- **Primary Source:** medRxiv (Clinical Preprints)
- **Source URL:** [Original Journal Publication](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1?rss=1)
- **Published At:** 2026-09-02T12:00:00.000Z
- **Evidence Rating:** Verified Feed
## Executive GIST (TL;DR)
- Study validated the **Brief-COPE** questionnaire in a German sample of patients with **seropositive rheumatoid arthritis (RA)**, addressing uncertainty about the instrument's factor structure in this population. - 216 outpatients with seropositive RA completed the Brief-COPE questionnaire; data were analyzed using exploratory factor analysis (EFA) with principal axis factoring and Promax rotation. - EFA supported a **five-factor solution** that together explained 51.95% of variance in coping responses. - The five identified factors were: **problem-focused coping** (Cronbach's α = 0.851), **emotion-focused coping** (α = 0.754), **maladaptive coping** (α = 0.747), **religious coping** (α = 0.851), and **substance-use coping** (α = 0.869). - Authors conclude the five-factor model best represents the Brief-COPE structure in seropositive RA and may be a suitable basis for future Brief-COPE analyses in similar RA populations. - Ethical approval was granted by the Ethical Committee of Hannover Medical School (approval number 3638 2017) and participant consent procedures were followed. - Data from the study are available on reasonable request to the authors; the work was posted as a medRxiv preprint on September 02, 2026 and lists funding from the Federal Joint Committee (G-BA), 01NVF16029. - Competing interest disclosures for several authors are provided in the source; details include speaking fees, honoraria, advisory roles, and research support from various industry and funding sources. - The study does not report confirmatory factor analysis results, external validity testing, or comparisons with other RA subgroups; such details were not reported in the source.
## Clinical Analysis & Structured Key Points
[](https://www.medrxiv.org/cdn-cgi/content?id=KwI1bUHrIWiojqweGcuFMIY7KiLyh0xeFyFWDu3h248-1788362397.49545-1.2.1.1-XaDH.G6E5vvAgq.dm61ey5wuYGaakgrlFcG_wq_9rGXkpMNHBC4RUosaLRA8OrUw) [Skip to main content](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1?rss=1#main-content) [![medRxiv](https://www.medrxiv.org/sites/default/files/medrxiv_inner_logo.png)](https://www.medrxiv.org/) * [Home](https://www.medrxiv.org/) * [Submit](https://www.medrxiv.org/submit-a-manuscript) * [FAQ](https://www.medrxiv.org/about/FAQ) * [Blog](https://connect.medrxiv.org/news/) * [ALERTS / RSS](https://www.medrxiv.org/content/alertsrss) * [Resources](https://connect.medrxiv.org/resources/) * [About](https://www.medrxiv.org/content/about-medrxiv) Search for this keyword [Advanced Search](https://www.medrxiv.org/search) Follow this preprint # Validation of the Brief-Cope Questionnaire in a Seropositive Rheumatoid Arthritis Population Ioana Iliadis, Ivo Heitland, Kirsten Hoeper, Torsten Witte, Kai G. Kahl, Britta Stapel, Dirk Meyer-Olson doi: https://doi.org/10.64898/2026.08.28.26361589 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Ioana Iliadis 1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ioana%2BIliadis%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Iliadis%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIoana%2BIliadis%2B) * For correspondence: iliadis.ioana@mh-hannover.de Ivo Heitland 1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Ivo%2BHeitland%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Heitland%20I&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AIvo%2BHeitland%2B) Kirsten Hoeper 2 Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kirsten%2BHoeper%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Hoeper%20K&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKirsten%2BHoeper%2B) Torsten Witte 2 Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Torsten%2BWitte%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Witte%20T&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ATorsten%2BWitte%2B) Kai G. Kahl 1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Kai%2BG.%2BKahl%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Kahl%20KG&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3AKai%2BG.%2BKahl%2B) Britta Stapel 1 Department of Psychiatry, Social Psychiatry and Psychotherapy, Hannover Medical School, Hanover, Germany; * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Britta%2BStapel%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Stapel%20B&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ABritta%2BStapel%2B) Dirk Meyer-Olson 2 Department of Rheumatology and Immunology, Hannover Medical School, Hanover, Germany * [Find this author on Google Scholar](https://www.medrxiv.org/lookup/google-scholar?link_type=googlescholar&gs_type=author&author%5B0%5D=Dirk%2BMeyer-Olson%2B "Open in new tab") * [Find this author on PubMed](https://www.medrxiv.org/lookup/external-ref?access_num=Meyer-Olson%20D&link_type=AUTHORSEARCH "Open in new tab") * [Search for this author on this site](https://www.medrxiv.org/search/author1%3ADirk%2BMeyer-Olson%2B) * [Abstract](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_art/node:1290134/1) * [Info/History](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1.article-info)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_info/node:1290134/1) * [Metrics](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1.article-metrics)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_metrics/node:1290134/1) * [Data/Code](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1.external-links)[](https://www.medrxiv.org/panels_ajax_tab/article_tab_data_code/node:1290134/1) * [ Preview PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1.full.pdf+html)[](https://www.medrxiv.org/panels_ajax_tab/biorxiv_tab_pdf/node:1290134/1) ![Loading](https://www.medrxiv.org/sites/all/modules/contrib/panels_ajax_tab/images/loading.gif) ## Abstract Objective: The Brief-cope questionnaire explore coping behavior. However, the underlying factor structure remains a subject of ongoing debate. Exploratory factor analyses (EFA) conducted across different populations have identified factor solutions ranging from two to fourteen factors. As of yet, the underlying factor structure of the Brief-cope has not been investigated in patients with seropositive rheumatoid arthritis (RA). Therefore, the aim of this study was to explore the underlying factor structure of the Brief-cope in a German population of seropositive RA. Methods: 216 outpatients with seropositive RA completed the Brief-cope. An EFA with principal axis factoring and Promax rotation was conducted. Results: EFA indicated a five-factor solution. The five-factor solution explained 51.95% of variance. The identified factors were: (1) problem-focused coping (Cronbach's α = .851), (2) emotion-focused coping (α = .754), (3) maladaptive coping (α = .747), (4) religious coping (α = .851), and (5) substance-use coping (α = .869). Conclusion: A five-factor solution provided the most appropriate representation of the underlying factor structure of the Brief-cope in patients with seropositive RA. This factor structure may serve as a suitable basis for future analyses of Brief-cope data in comparable RA populations. ### Competing Interest Statement Ioana Iliadis: none Dr. Ivo Heitland: IH received speaking fees and travel expense reimbursements from DGK Akademie, AudiBKK, TUIBKK, Bundesagentur fuer Arbeit, Jobcenter Region Hannover, TUI, AANB e.V. and CJD Wolfsburg, which are not related to this article. Dr. Kirsten Hoeper: Honoraria, travel support, and accommodation expenses: AbbVie, Chugai, Medac, UCB, European Alliance of Associations for Rheumatology (EULAR). Prof. Dr. Torsten Witte: Honoraria, travel support, and accommodation expenses: AbbVie, Alfasigma, Amgen, Argenx, AstraZeneca, Boehringer Ingelheim, Chugai, Fresenius Kabi, GSK, Hexal, Janssen, Lilly, Medac, Nordic, Novartis, Roche, Sanofi, Takeda, UCB. Prof. Dr. Kai G. Kahl: Honoraria, travel support, and accommodation expenses: Takeda, Idorsia, Eli Lilly, Servier, Dr. Schwabe, Janssen/Johnson & Johnson, Alexion, Berlin-Chemie. Scientific advisory board: Navel Robotics. Research funding: German Federal Ministry of Education and Research (BMBF), German Research Foundation (DFG), JobCenter Hannover, Volkswagen Foundation, Else Kroener-Fresenius Foundation, MHHplus Foundation. Professional memberships: German Association for Psychiatry, Psychotherapy and Psychosomatics (DGPPN; Co-Chair of the Psychosomatics Section); Association for Neuropsychopharmacology and Pharmacopsychiatry (AGNP; Chair of the Polypharmacy Working Group). Dr. Britta Stapel: none Prof. Dr. Dirk Meyer-Olson: Scientific advisory board, speaker fees and/or research support: Abbvie GmbH & Co KG, Alfasigma GmbH, Glaxo Smith Kline GmbH & Co. KG, Medac GmbH Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, UCB Pharma GmbH. ### Author Declarations I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained. Yes The details of the IRB/oversight body that provided approval or exemption for the research described are given below: Ethical committee of Hannover Medical School gave ethical approval for this work (number 3638 2017). I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals. Yes I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance). Yes I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable. Yes ## Data Availability All data produced in the present study are available upon reasonable request to the authors. ## Funder Information Declared Federal Joint Committee (G- BA), 01NVF16029 Copyright The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. bioRxiv and medRxiv thank the following for their generous financial support: > The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, The University of Edinburgh, University of Washington, and Vrije Universiteit Amsterdam. [Donate to openRxiv ](https://www.zeffy.com/en-US/donation-form/donate-to-make-a-difference-10981) [ Back to top](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1?rss=1#page) [ Previous](https://www.medrxiv.org/content/10.64898/2026.08.30.26361786v1 "Feasibility study of gait analysis using a new Wearable Force Plate")[Next ](https://www.medrxiv.org/content/10.64898/2026.08.28.26361368v1 "GLP-1/GIP Uptake, Indication, and Access Pathways Among US Adults in the Understanding America Study") Posted September 02, 2026. [ Download PDF](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1.full.pdf) Print/Save Options [Download PDF](https://www.medrxiv.org/content/medrxiv/early/2026/09/02/2026.08.28.26361589.full.pdf)Full Text & In-line FiguresXML [More Info](https://www.medrxiv.org/about/FAQ#PrintOptions "More Information on Print/Save Options") [ Author Declarations](https://www.medrxiv.org/content/10.64898/2026.08.28.26361589v1#p-5) [ Data/Code](https://www.medrxiv.org/content/early/2026/09/02/2026.08.28.26361589.external-links) [ Email](https://www.medrxiv.org/ "Email this Article") [ Share](https://www.medrxiv.org/) Validation of the Brief-Cope Questionnaire in a Seropositive Rheumatoid Arthritis Population Ioana Iliadis, Ivo Heitland, Kirsten Hoeper, Torsten Witte, Kai G. Kahl, Britta Stapel, Dirk Meyer-Olson medRxiv 2026.08.28.26361589; doi: https://doi.org/10.64898/2026.08.28.26361589 [This article is a preprint and has not been certified by peer review [](https://www.medrxiv.org/about/FAQ#unrefereed)[what does this mean?](https://www.medrxiv.org/about/FAQ#unrefereed)]. It reports new medical research that has yet to be evaluated and so should _not_ be used to guide clinical practice. Share This Article: Copy [![Twitter logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/twitter.png)](https://www.medrxiv.org/highwire_log/share/twitter?link=http%3A%2F%2Ftwitter.com%2Fshare%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361589v1%26text%3DValidation%2520of%2520the%2520Brief-Cope%2520Questionnaire%2520in%2520a%2520Seropositive%2520Rheumatoid%2520Arthritis%2520Population "Share this on Twitter") [![Facebook logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/fb-blue.png)](https://www.medrxiv.org/highwire_log/share/facebook?link=http%3A%2F%2Fwww.facebook.com%2Fsharer.php%3Fu%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361589v1%26t%3DValidation%2520of%2520the%2520Brief-Cope%2520Questionnaire%2520in%2520a%2520Seropositive%2520Rheumatoid%2520Arthritis%2520Population "Share on Facebook") [![LinkedIn logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/linkedin-32px.png)](https://www.medrxiv.org/highwire_log/share/linkedin?link=http%3A%2F%2Fwww.linkedin.com%2FshareArticle%3Fmini%3Dtrue%26url%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361589v1%26title%3DValidation%2520of%2520the%2520Brief-Cope%2520Questionnaire%2520in%2520a%2520Seropositive%2520Rheumatoid%2520Arthritis%2520Population%26summary%3D%26source%3DmedRxiv "Publish this post to LinkedIn") [![Mendeley logo](https://www.medrxiv.org/sites/all/modules/highwire/highwire/images/mendeley.png)](https://www.medrxiv.org/highwire_log/share/mendeley?link=http%3A%2F%2Fwww.mendeley.com%2Fimport%2F%3Furl%3Dhttps%253A%2F%2Fwww.medrxiv.org%2Fcontent%2F10.64898%2F2026.08.28.26361589v1%26title%3DValidation%2520of%2520the%2520Brief-Cope%2520Questionnaire%2520in%2520a%2520Seropositive%2520Rheumatoid%2520Arthritis%2520Population "Share on Mendeley") [ Citation Tools](https://www.medrxiv.org/ "Citation Tools") [ Get QR code](https://connect.medrxiv.org/qr/2026.08.28.26361589) * [Tweet Widget](http://twitter.com/share?url=https%3A//www.medrxiv.org/content/10.64898/2026.08.28.26361589v1&count=horizontal&via=&text=Validation%20of%20the%20Brief-Cope%20Questionnaire%20in%20a%20Seropositive%20Rheumatoid%20Arthritis%20Population&counturl=www.medrxiv.org/content/10.64898/2026.08.28.26361589v1 "Tweet This") Reviews and Context 0 Comment 0 TRIP Peer Reviews 0 Community Reviews 0 Automated Services 0 Blogs/Media 0 Author Videos **Subject Areas** [**All Articles**](https://www.medrxiv.org/content/early/recent) * [Addiction Medicine](https://www.medrxiv.org/collection/addiction-medicine) (614) * [Allergy and Immunology](https://www.medrxiv.org/collection/allergy-and-immunology) (896) * [Anesthesia](https://www.medrxiv.org/collection/anesthesia) (326) * [Cardiovascular Medicine](https://www.medrxiv.org/collection/cardiovascular-medicine) (4770) * [Dentistry and Oral Medicine](https://www.medrxiv.org/collection/dentistry-and-oral-medicine) (474) * [Dermatology](https://www.medrxiv.org/collection/dermatology) (407) * [Emergency Medicine](https://www.medrxiv.org/collection/emergency-medicine) (643) * [Endocrinology (including Diabetes Mellitus and Metabolic Disease)](https://www.medrxiv.org/collection/endocrinology-including-diabetes-mellitus-and-metabolic-disease) (1614) * [Epidemiology](https://www.medrxiv.org/collection/epidemiology) (15835) * [Forensic Medicine](https://www.medrxiv.org/collection/forensic-medicine) (32) * [Gastroenterology](https://www.medrxiv.org/collection/gastroenterology) (1194) * [Genetic and Genomic Medicine](https://www.medrxiv.org/collection/genetic-and-genomic-medicine) (6983) * [Geriatric Medicine](https://www.medrxiv.org/collection/geriatric-medicine) (727) * [Health Economics](https://www.medrxiv.org/collection/health-economics) (1057) * [Health Informatics](https://www.medrxiv.org/collection/health-informatics) (4982) * [Health Policy](https://www.medrxiv.org/collection/health-policy) (1426) * [Health Systems and Quality Improvement](https://www.medrxiv.org/collection/health-systems-and-quality-improvement) (1736) * [Hematology](https://www.medrxiv.org/collection/hematology) (581) * [HIV/AIDS](https://www.medrxiv.org/collection/hiv-aids) (1336) * [Infectious Diseases (except HIV/AIDS)](https://www.medrxiv.org/collection/infectious_diseases) (16244) * [Intensive Care and Critical Care Medicine](https://www.medrxiv.org/collection/intensive-care-and-critical-care-medicine) (1161) * [Medical Education](https://www.medrxiv.org/collection/medical-education) (663) * [Medical Ethics](https://www.medrxiv.org/collection/medical-ethics) (151) * [Nephrology](https://www.medrxiv.org/collection/nephrology) (720) * [Neurology](https://www.medrxiv.org/collection/neurology) (7194) * [Nursing](https://www.medrxiv.org/collection/nursing) (363) * [Nutrition](https://www.medrxiv.org/collection/nutrition) (1074) * [Obstetrics and Gynecology](https://www.medrxiv.org/collection/obstetrics-and-gynecology) (1231) * [Occupational and Environmental Health](https://www.medrxiv.org/collection/occupational-and-environmental-health) (1001) * [Oncology](https://www.medrxiv.org/collection/oncology) (3573) * [Ophthalmology](https://www.medrxiv.org/collection/ophthalmology) (1036) * [Orthopedics](https://www.medrxiv.org/collection/orthopedics) (393) * [Otolaryngology](https://www.medrxiv.org/collection/otolaryngology) (446) * [Pain Medicine](https://www.medrxiv.org/collection/pain-medicine) (466) * [Palliative Medicine](https://www.medrxiv.org/collection/palliative-medicine) (139) * [Pathology](https://www.medrxiv.org/collection/pathology) (704) * [Pediatrics](https://www.medrxiv.org/collection/pediatrics) (1772) * [Pharmacology and Therapeutics](https://www.medrxiv.org/collection/pharmacology-and-therapeutics) (733) * [Primary Care Research](https://www.medrxiv.org/collection/primary-care-research) (759) * [Psychiatry and Clinical Psychology](https://www.medrxiv.org/collection/psychiatry-and-clinical-psychology) (5832) * [Public and Global Health](https://www.medrxiv.org/collection/public-and-global-health) (9691) * [Radiology and Imaging](https://www.medrxiv.org/collection/radiology-and-imaging) (2387) * [Rehabilitation Medicine and Physical Therapy](https://www.medrxiv.org/collection/rehabilitation-medicine-and-physical-therapy) (1432) * [Respiratory Medicine](https://www.medrxiv.org/collection/respiratory-medicine) (1241) * [Rheumatology](https://www.medrxiv.org/collection/rheumatology) (633) * [Sexual and Reproductive Health](https://www.medrxiv.org/collection/sexual-and-reproductive-health) (766) * [Sports Medicine](https://www.medrxiv.org/collection/sports-medicine) (576) * [Surgery](https://www.medrxiv.org/collect
## Related Clinical Research

- [Climate change worsens health for people with chronic illness](https://medichelpline.com/clinical-feed/stat-news-1-opinion-climate-change-is-making-people-with-chronic-illness-even-sicker.md)
- [Gut microbial structural variation enhances RA discrimination and reveals a strain-level regulator](https://medichelpline.com/clinical-feed/medrxiv-13-gut-microbial-structural-variation-improves-disease-discrimination-and-reveals.md)
- [Resveratrol as an Adjunct to DMARDs in Long-Standing Rheumatoid Arthritis: Effects on Low-Grade In](https://medichelpline.com/clinical-feed/medrxiv-12-complementary-use-of-resveratrol-improves-low-grade-chronic-inflammation.md)
- [Case report: ADMIO type 1 linked to de novo STAT3 gain-of-function mutation](https://medichelpline.com/clinical-feed/frontiers-in-immunology-16-a-case-report-of-admio-type-1-caused-by-a-de-novo-stat3-gain-of-function.md)
- [Semaglutide and Primary Prevention of MACCE in Obese Adults with T2DM and Rheumatoid Arthritis](https://medichelpline.com/clinical-feed/pubmed-42334436.md) (DOI: 10.1093/ehjcvp/pvag044)

## Navigation
- [← Back to General Feed](https://medichelpline.com/clinical-feed/general.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.